First name,Last name,Preferred title,Overview,Position,Department,Individual
Sathish,Dharani,Research Assistant Professor,,Research Assistant Professor,Pharmacy Practice,https://scholars.library.tamu.edu/vivo/display/n0373e83e
Carolyn,Cannon,Associate Professor,"Our goal is to develop novel, non-toxic antimicrobial formualtions with efficacy against gram-positive and gram-negative multi-drug resistant pathogens.",Associate Professor,Microbial Pathogenesis and Immunology,https://scholars.library.tamu.edu/vivo/display/n0b3870aa
Ziyaur,Rahman,Associate Professor,"Over 17 years of research experience in the general areas of pharmaceutical sciences and drug delivery systems, with special expertise in the area of formulation design and process development. Research areas are: 1) formulation and process design of complex drug delivery systems (such as liposomes, nanoparticles, transdermal, implant, emulsions, microspheres, pediatric etc.); 2) improving drug product quality as well as process understanding through Quality by Design (QbD) approach and Process Analytical Technologies (PAT); 3) development of in vitro release performance tests for traditional (tablets, capsules, gels, emulsions) as well as complex drug delivery systems (microspheres, liposomes, nanoparticles, transdermal, implant, emulsions, ointments, creams, etc.); 4) evaluation of bio-equivalence of complex drug dosage forms; 5) design and evaluation of abuse deterrent formulations (ADF) for opioid analgesics, 6) 3-dimensional printing of various dosage forms for pharmaceutical application, 7) continuous manufacturing of pharmaceutical dosage forms and 8) univariate and multivariate models (chemometrics, mega-data analysis) development for various phases (polymorphs, amorphous, solvates, salt or base) quantification in the drug products. Other areas of intense research interest include protein and peptide delivery using polymeric materials in formulation design and risk analysis.",Associate Professor,Irma Lerma Rangel School of Pharmacy,https://scholars.library.tamu.edu/vivo/display/n0fc48989
Lisa,Even,Manager Laboratory,,Manager Laboratory,Small Animal Clinical Sciences,https://scholars.library.tamu.edu/vivo/display/n24b36cbf
Dzmitry,Kurouski,Assistant Professor,"My laboratory is broadly interested in elucidation of structural organization of amyloid oligomers using Tip-Enhanced Raman Spectroscopy (TERS).
The ultimate objective of our studies is to unravel structural elements on surfaces of amyloid oligomers that are responsible for their toxicity and propensity to propagate into amyloid fibrils. These findings will help to guide pharmaceutical drug screening efforts towards finding selective blockaders of amyloid fibrillation at the stage where their aggregates are minimally toxic. Finally, resolving the structure of amyloid oligomers will give an inside how to cure Alzheimer's and Parkinson's diseases and dementia.",Assistant Professor,Biochemistry and Biophysics,https://scholars.library.tamu.edu/vivo/display/n43453d43
Simi,Gunaseelan,Director of Assessment and Instructional Associate Professor,,Director of Assessment and Instructional Associate Professor,Pharmaceutical Sciences,https://scholars.library.tamu.edu/vivo/display/n591eec4c
Fred,Clubb,Clinical Professor,"Providing innovative, objective pathology support of the utmost quality to improve medical device technologies and subsequently, patients' lives and creating learning opportunities and new knowledge for students and the scientific community.",Clinical Professor,Veterinary Pathobiology,https://scholars.library.tamu.edu/vivo/display/n62494da9
Marcetta,Darensbourg,Distinguished Professor,"Bio-inspired Catalysts for Hydrogen Production: The ultimate, home-run, goal of our work is to synthesize and develop a robust, highly active hydrogen-producing catalyst comprised of earth-abundant transition metals within a ligand environment that is inspired by the biological Figure 3hydrogenase (H2ase) enzyme active sites. Progress in precise structural modeling of the illusive ""rotated"" structure displayed in the as-isolated, mixed-valent FeIIFe state in the past decade has permitted in depth analysis of electronic structure by Mo ssbauer, EPR (ENDOR), and computational chemistry. New electrocatalysts for hydrogen production: The connection between the Fe(NO)2 unit and the Fe(CX)3 (X = O or N) unit found in hydrogenase enzyme active sites offers opportunity for design of new catalysts, one of which is shown. In this regard we explore the ability of N2S2 metal complexes to bind as metallodithiolate ligands to various metal acceptors. The properties of such complexes vary The connection of these to light harvesting molecules for dye sensitized, sacrificial electron donor, hydrogen production is also of interest. When Iron Meets Nitric Oxide: Good Chemistry, Intriguing Biology. The affinity of iron for diatomic molecules, O2, CO, N2, and NO, is central to the most important of life processes, including those of human physiology. Figure 6In this research area we target synthetic chemistry involving dinitrosyl iron complexes (DNICs) that serve as biomimetics of products of FeS cluster degradation by excesses of NO, or as derived from the chelatable iron pool (CIP) in cells. The electronic ambivalence of the DNIC unit is expressed in the ease with which it interconverts between oxidized and reduced forms, {Fe(NO)2}9 and {Fe(NO)2}10, respectively (Enemark/Feltham notation), and serves as impetus to explore analogous reactions known to involve the CuII/CuI redox couple. The accessory ligands which stabilize one redox level over the other, including N-heterocyclic carb",Distinguished Professor||Faculty Affiliate,Energy Institute||Chemistry,https://scholars.library.tamu.edu/vivo/display/n6f445741
Phapanin,Charoenphol,Instructional Assistant Professor,,Instructional Assistant Professor,Mechanical Engineering,https://scholars.library.tamu.edu/vivo/display/n754c604c
Karen,Wooley,Distinguished Professor,"Our research activities combine organic syntheses, polymerization strategies and polymer modification reactions in creative ways to afford unique macromolecular structures, which have been designed as functional nanostructures, polymer systems having unique macromolecular architectures, and/or degradable polymers. The emphasis is upon the incorporation of functions and functionalities into selective regions of polymer frameworks. In some cases, the function is added at the small molecule, monomer, stage, prior to polymerization, whereas, in other cases, chemical modifications are performed upon polymers or at the nanostructure level; each requires a strategic balance of chemical reactivity and the ultimate composition and structure.",Distinguished Professor,Chemistry,https://scholars.library.tamu.edu/vivo/display/n7d5d2fbd
James,Sacchettini,Professor,"My lab uses X-ray crystallography to better understand the relationship between proteins and ligands. Tiny differences in the structure of a molecule can radically change the interaction between a protein and ligand and we are only begining to understand how many factors play a role in this interaction. By manipulating the individual components of a compound it is possible to create a chemical that binds to the protein better than the natural substrate, and prevent the natural reaction from occurring. This is the basis for rational drug design. Our efforts have lead us to collaborations with other labs and scientists in many disciplines as our approach to directed compound design has applications not only in basic research but also in pesticide development, health research and clinical research.",Professor,Biochemistry and Biophysics,https://scholars.library.tamu.edu/vivo/display/n90385563
Jodie,Lutkenhaus,Professor,"Dr. Lutkenhaus's lab explores polymers for plastic power, enabling flexible or structural batteries and capacitors, as well as polyelectrolytes, which are integral components in smart surfaces and coatings.",Professor,Chemical Engineering,https://scholars.library.tamu.edu/vivo/display/na0bd3380
Mustafa,Akbulut,Associate Professor,"The Akbulut Lab is involved in research in various areas of nanotechnology, surface and interface science, with a special focus on the areas of drug delivery, biomedical interfaces, tribology, surface and intermolecular forces, colloidal stabilization, and crystallization.",Associate Professor||Faculty Affiliate||Associate Professor,Energy Institute||Chemical Engineering||Materials Science and Engineering,https://scholars.library.tamu.edu/vivo/display/nb5e5f93d
Lin,Zhu,Associate Professor,,Associate Professor,Irma Lerma Rangel School of Pharmacy,https://scholars.library.tamu.edu/vivo/display/nb936a5d7
Duane,Kraemer,Senior Professor - Term Appointment,,Senior Professor - Term Appointment,Veterinary Physiology and Pharmacology,https://scholars.library.tamu.edu/vivo/display/nb976606f
Mathew,Kuttolamadom,Associate Professor,,Faculty Affiliate||Faculty Affiliate||Associate Professor||Associate Professor,Engineering Technology and Industrial Distribution||Energy Institute||Materials Science and Engineering||Institute for Engineering Education and Innovation,https://scholars.library.tamu.edu/vivo/display/nbd4de409
Kevin,Burgess,Professor,"We use novel strategies Exploring Key Orientations (EKO) that feature datamining to compare simulated preferred conformers of chemotypes we design with key features at protein-protein interfaces. Many chemotype candidates can be screened against one PPI, or one chemotype can be screened against all the PPI interfaces in the PDB. Virtual hit chemotypes are prepared in my lab, then tested against protein-protein interactions of biomedicinal interest using an array of biophysical and cellular assays.
We also design small molecules to target cell surface receptors that are selectively overexpressed in cancer cells. Much or our work has been focused on the TrkC receptor that is particularly important to metastatic breast cancer and melanoma. Going forwards we are interested in expanding the targets to include cell surface receptors that are overexpressed when cancer cells undergo aberrant epithelial to mesenchymal transitions (EMT) to produce circulating tumor cells and cancer stem cells. Much of this work involves design and synthesis of the small molecules for this targeting.",Professor,Chemistry,https://scholars.library.tamu.edu/vivo/display/nc4a5cad4
Xin,Yan,Assistant Professor,"At the Yan lab, we seek to develop and apply novel mass spectrometric methodologies in disease diagnosis, reaction monitoring, and development of new synthetic methods. In particular, we are motivated by the possibility of enabling new technology for next-generation approaches to precision medicine, and sustainable synthesis.
Our research interests span a range of topics, including i) metabolomics in brain research: we couple dual imaging modality (mass spectrometry imaging and fluorescence imaging) with liquid chromatography mass spectrometry to discover biomarkers and elucidate their biological mechanism in brain aging and brain cancer research. ii) point-of-care diagnostics: we are interested in the development of ambient ionization for fast analysis of enzymatic biomarkers, as well as the design and development of the interface to mini-mass spectrometer (mini-MS) for point-of-care diagnosis. iii) microdroplet reaction: mass spectrometry is universally considered as an analytical tool, however, its new feature was discovered: its use as a unique tool in synthesis. The uniqueness represents in its capabilities of dramatical acceleration of organic reactions and the driving of reactions that cannot occur in bulk. We aim to develop microdroplet reactors for acceleration, explore new reactivity, and study fundamentals of microdroplet acceleration. iv) reaction mechanistic study: reaction mechanisms play an essential role in the study of organic chemistry. We aim to develop new online mass spectrometric reaction monitoring system to explore unknown reaction mechanism, capture short-lived intermediates, study kinetics of fast reactions, and control process of active pharmaceutical ingredient (API) synthesis. The central theme of all the topics above is about droplet chemistry.
This lab is a highly interdisciplinary research group. It provides students the opportunity to obtain hands-on experience in analytical, biological and synthetic chemistry.",Assistant Professor,Chemistry,https://scholars.library.tamu.edu/vivo/display/nc863cc6e
Isaac,Adjei,Assistant Professor,"Dr. Isaac Adjei's goals are to advance translatable strategies to understand, treat and diagnose cancer, and in the process educate the next generation of scientists. His research focuses on developing drug delivery systems that improve outcomes for advanced-stage cancer. He also studies the mechanisms of tumor immune evasion using three-dimensional tumor models, with the goal of developing novel strategies to reactivate the immune system against tumors.",Assistant Professor,Biomedical Engineering,https://scholars.library.tamu.edu/vivo/display/nce137c7b
Mansoor,Khan,Professor and Vice Dean,"Dr. Mansoor A. Khan serves as a professor and Vice Dean of the Texas A&M University Rangel College of Pharmacy at College Station, Texas. Prior to joining Texas A&M in 2015, he served as the Director of Product Quality Research and a Senior Biomedical Research Scientist (SBRS) at CDER in US Food and Drug Administration for over eleven years. In FDA, he led the research and review teams to promote manufacturing science, and served as a founding member of the FDA Emerging Technology Team. Dr. Khan received his Ph.D. degree in industrial pharmacy form St. Johns University in NY. He has published over 335 peer-reviewed manuscripts in pharmaceutical formulations and manufacturing sciences, and delivered over 300 presentations world-wide. Dr. Khan's research, currently supported by the NIH and FDA, spans drug delivery and formulations, and he has received over ten million dollars in funding as a principal investigator.
Dr. Khan has held leadership positions at the AAPS including elected chair of formulations design and development (FDD) section. He serves on the editorial board of Pharmaceutical Technology, International Journal of Pharmaceutics, AAPSPharmsciTech, and the Drug Delivery and Translational Research. He has received about 20 FDA/CDER review, research, and exemplary achievement awards, outstanding alumni award at St. Johns University College of Pharmacy, Excellence Award in Texas A&M University. He received the 2012 AAPS Research Achievement Award in Formulations Design and Development. He is also an AAPS and AAiPS Fellow. Dr. Khan served as FDA representative to the World Health Organization (WHO), United States Pharmacopoeia (USP), European Medicine Agency (EMA), DARPA, NIH, National Institute of Pharmaceutical Technology and Education (NIPTE), and International Pharmaceutical Federation (FIP). He is also a member of the European Union Academy of Sciences.",Regents Professor and Presidential Impact Fellow,Center for Microencapsulation and Drug Delivery,https://scholars.library.tamu.edu/vivo/display/nfc5f1cd6